Nurix Therapeutics Inc is trading 5.1% up today at $17.84, extending a sharp rally driven by breakthrough clinical data for its lead blood cancer treatment.
- Shares surged following updated trial results presented on June 11, 2026, which demonstrated a 93% response rate for the company's lead drug candidate.
- The continued upward momentum suggests investors are aggressively reassessing the company’s valuation and long-term revenue potential based on the strong efficacy signal.